On the evening of April 22, Bgi Genomics Co.Ltd(300676) ( Bgi Genomics Co.Ltd(300676) . SZ) released the annual report of 2021 and the first quarterly report of 2022. In 2021, the company realized an operating revenue of 6.766 billion yuan and a net profit attributable to shareholders of listed companies of 1.462 billion yuan Bgi Genomics Co.Ltd(300676) at the same time, the first quarter report of 2022 disclosed that the company achieved a revenue of 1.43 billion yuan in the first quarter of this year and a net profit attributable to shareholders of listed companies of 330 million yuan.
Bgi Genomics Co.Ltd(300676) said that due to the decline in the global unit price of covid-19 nucleic acid reagent and detection, as well as the changes in epidemic prevention strategies in some countries and regions, the company took the initiative to strategically adjust covid-19 related product structure and supply chain strategy, and the business income based on covid-19 in 2021 decreased compared with the higher base in the same period of 2020. Meanwhile, in the first quarter of 2022, the company actively participated in the aid to Hong Kong to fight the epidemic. The settlement progress of some businesses was affected by the epidemic, and the revenue has not been recognized yet.
In terms of business, Bgi Genomics Co.Ltd(300676) maintains a leading position in the field of reproductive health. In 2021, driven by multiple factors such as testing business increment, new technology breakthrough and product renewal iteration, the current operating revenue of Bgi Genomics Co.Ltd(300676) reproductive health business was RMB 1.192 billion, with a year-on-year increase. By the end of 2021, Bgi Genomics Co.Ltd(300676) non invasive prenatal genetic testing services had exceeded 10 million.
In terms of cancer prevention and control business, Bgi Genomics Co.Ltd(300676) 2021 achieved a revenue of 380 million yuan, a year-on-year increase of 8.12%; In terms of infection prevention and control business, its revenue was 1.158 billion yuan, a year-on-year increase of 73.01%; In the field of multi omics big data and synthesis, Bgi Genomics Co.Ltd(300676) achieved a revenue of 642 million yuan, a year-on-year increase of 2.5%.
In the field of comprehensive solutions for precision medical testing, Bgi Genomics Co.Ltd(300676) achieved a revenue of 3.382 billion yuan, accounting for 49.99% of the revenue. Through years of intensive cultivation, Bgi Genomics Co.Ltd(300676) precision medical testing integrates cutting-edge science and technology and traditional medical methods, and provides a new comprehensive medical solution throughout the whole life cycle for healthy China, which is expected to empower the global life and health industry in the future.
Bgi Genomics Co.Ltd(300676) main business growth is inseparable from its continuous focus on R & D investment. In 2021, Bgi Genomics Co.Ltd(300676) R & D investment totaled 542 million yuan, with 825 R & D personnel. By the end of 2021, a total of 531 patents have been granted, and 742 software copyrights have been obtained for independent software.
It is worth mentioning that as one of the important forces in the global fight against the epidemic, Bgi Genomics Co.Ltd(300676) continues to strengthen the global market development, meet the dynamic market demand for global epidemic prevention and control through continuous R & D and innovation, seize the opportunity of the construction and expansion of the global precision medicine service system in the post epidemic era, and comprehensively deepen the international business expansion in terms of product qualification, localization strategic planning, quality system and other dimensions, Realize the sustainable development of overseas business.
Bgi Genomics Co.Ltd(300676) said that through this epidemic, more countries and regions have realized the importance of public health localization capacity-building and local industrial ecological development. The new infrastructure model of "prevention first" public health is expected to be popularized internationally. As a practitioner of the public health concept of "prevention first" and a leading enterprise in the industry, the company actively summarizes experience and strives to create a stable and high-quality long-term development model.
